Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Publisher: Renub Research
Published: June 2010

---

Report Details

"Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug),
Insulin, DPP-IV, GLP-1" report published by Renub Research provides an in-depth analysis of
the past, present and future prospects. The report has been researched at source globally,
country specific and features latest available data covering:

Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
Region wise Diabetes Health Expenditure and Mortality
Top 10 Countries Diabetes Population and Future Forecast
Top 5 Countries Diabetes Drug Market and Future Forecast
Top 7 Countries Insulin Market and Future Forecast
Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm,
Starlix) data of Past, Present and Future Market
Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog,
Humulin, Apidra, Lantus) data of Past, Present and Future Market
Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past,
Present and Future Market
Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of
Past, Present and Future Market

Research Highlights

USA controls more than 50% of the total Diabetes Drug market share in 2009
Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
China will have the second highest Insulin market share by 2012 replacing Germany
DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3
Billion by 2015.
(c) Renub Research Page 2 of 18

---

Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and
cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
Januvia is proving a blockbuster of DPP - IV Inhibitors segment expected to be more
than US$ 4 Billion by 2017
Last year launched Victoza and yet to be launched Exenatide LAR is going to be
blockbuster GLP-1 Agonists
China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Key Drugs Analyzed

Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra,
Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide

Data Sources

Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.











(c) Renub Research Page 3 of 18

---

Published By

Renub Research
A-116B, Sector-27
Noida - 201301
Phone: +91-120-421-9822, 424-9780 (India)
+1-678-302-0700 (US)
Email: info@renub.com
www.renub.com







(c) Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-
IV, GLP-1
Renub Research, 2010
Edition 1.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers.


(c) Renub Research Page 4 of 18

---

Table of Contents

1.
Executive Summary
2.
Global Diabetes Market
2.1
Global - Diabetes Drug Market & Future Forecast
2.2
Global - Insulin Market & Future Forecast
2.3
Global - Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)
2.4
Global - Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan,
USA, India)
2.5
Global - Dipeptidyl Peptidase (DPP - IV) Inhibitors Market & Future Forecast
2.6
Global - Glucagon-like Peptide-1(GLP-1) Market & Future Forecast
3.
Global - Top 6 Diabetes Drug Brands Market Performance
3.1
Avandia - Past & Present Market
3.2
Actos - Past, Present & Future Forecast
3.3
Amaryl - Past, Present & Future Forecast
3.4
Avandamet - Past, Present & Future Forecast
3.5
Prandin/Novonorm - Past & Present Market
3.6
Starlix - Past, Present & Future Forecast
4.
Global - Top 9 Insulin Brands Market Performance
4.1
Novomix - Past, Present & Future Forecast
4.2
Novorapid - Past, Present & Future Forecast
4.3
Levemir - Past, Present & Future Forecast
4.4
Degludec - Yet to be Launched - Future Forecast
4.5
Degludecplus - Yet to be Launched - Future Forecast
4.6
Humalog - Past & Present Market
4.7
Humulin - Past & Present Market
4.8
Apidra - Past, Present & Future Forecast
4.9
Lantus - Past, Present & Future Forecast
(c) Renub Research Page 5 of 18

---

5.
Global - DPP-IV Inhibitors Brands Market Performance
5.1
Januvia - Past, Present & Future Forecast
5.2
Onglyza - Past, Present & Future Forecast
5.3
Alogliptin - Yet to be Launched - Future Forecast
5.4
Galvus - Past, Present & Future Forecast
5.5
DPP-IV Inhibitors - In Trial Phases
6.
Global - GLP-1 Agonists Brands Market Performance
6.1
Byetta - Past, Present & Future Forecast
6.2
Victoza - Past, Present & Future Forecast
6.3
Exenatide LAR - Yet to be Launched - Future Forecast
6.4
Syncria - Yet to be Launched - Future Forecast
6.5
Taspoglutide - Yet to be Launched - Future Forecast
7.
Regional Estimates for Diabetes
7.1
Diabetes - Population & Prevalence
7.2
Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.3
Mortality - Due to Diabetes
7.4
North America & Caribbean Region
7.4.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.4.2
Healthcare Expenditure & Type 1 Diabetes
7.4.3
Mortality
7.5
Middle East and North African Region
7.5.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.5.2
Healthcare Expenditure & Type 1 Diabetes
7.5.3
Mortality
7.6
South-East Asian Region
7.6.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.6.2
Healthcare Expenditure & Type 1 Diabetes
7.6.3
Mortality
7.7
European Region
7.7.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.7.2
Healthcare Expenditures & Type 1 Diabetes
(c) Renub Research Page 6 of 18

---

7.7.3
Mortality
7.8
South and Central American Region
7.8.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.8.2
Healthcare Expenditures & Type 1 Diabetes
7.8.3
Mortality
7.9
Western Pacific Region
7.9.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.9.2
Healthcare Expenditures & Type 1 Diabetes
7.9.3
Mortality
7.10
African Region
7.10.1
Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
7.10.2
Healthcare Expenditure & Type 1 Diabetes
7.10.3
Mortality
8.
Global - Top 10 Diabetic Countries Performance
8.1
Number of People in Top 10 Diabetic Place
8.2
Prevalence of Diabetes in Top 10 Countries
8.3
India
8.3.1
Diabetes Population & Future Scenario
8.3.2
India - Diabetes Drug Market & Future Forecast
8.3.3
India-Insulin Market & Future Forecast
8.4
China
8.4.1
Diabetes Population & Future Scenario
8.4.2
Diabetes Drug Market & Future Forecast
8.4.3
China Insulin Market & Future Forecast
8.5
United States
8.5.1
Diabetes Population & Future Scenario
8.5.2
Diabetes Drug Market & Future Forecast
8.5.3
Insulin Market & Future Forecast
8.6
Brazil
8.6.1
Diabetes Population & Future Scenario
8.6.2
Diabetes Drug Market & Future Forecast
8.7
Russia
8.7.1
Diabetes Population & Future Scenario
8.7.2
Insulin Market & Future Forecast
(c) Renub Research Page 7 of 18

---

8.8
Japan
8.8.1
Diabetes Population & Future Scenario
8.8.2
Diabetes Drug Market & Future Forecast
8.8.3
Insulin Market & Future Forecast
8.9
Germany
8.9.1
Diabetes Population & Future Scenario
8.9.2
Insulin Market & Future Forecast
8.10
Mexico
8.10.1
Diabetes Population & Future Scenario
8.10.2
Insulin Market & Future Forecast
8.11
Indonesia
8.11.1
Diabetes Population & Future Scenario
8.12
Pakistan
8.12.1
Diabetes Population & Future Scenario




















(c) Renub Research Page 8 of 18

---

List of Figures:

Figure 2-1: Global - Diabetes Drug Market (Billion US$), 2005 - 2009
Figure 2-2: Global - Forecast of Diabetes Drug Market (Billion US$), 2010 - 2013
Figure 2-3: Global - Insulin Market (Billion US$), 2004 - 2009
Figure 2-4: Global - Forecast of Insulin Market (Billion US$), 2010 - 2013
Figure 2-5: Global - Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 -
2009
Figure 2-6: Global - Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India)
(Percent), 2010 - 2013
Figure 2-7: Global - Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India)
(Percent), 2007 - 2009
Figure 2-8: Global - Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA,
India) (Percent), 2010 - 2013
Figure 2-9: Global - DPP - IV Inhibitors Market (Million US$), 2009 - 2015
Figure 2-10: Global - GLP-1 Market (Million US$), 2009 - 2015
Figure 3-1: Global - Avandia Diabetes Drug Brand Sales (Million US$), 2004 - 2009
Figure 3-2: Global - Actos Diabetes Drug Sales (Billion US$), 2005 - 2009
Figure 3-3: Global - Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013
Figure 3-4: Global - Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010
Figure 3-5: Global - Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 - 2012
Figure 3-6: Global - Avandamet Diabetes Drug Sales (Million US$), 2006 - 2009
Figure 3-7: Global - Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 - 2012
Figure 3-8: Global - Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 - 2009
Figure 3-9: Global - Starlix Diabetes Drug Sales (Million US$), 2007 - 2009E
Figure 3-10: Global - Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 - 2012
Figure 4-1: Global - NovoMix Insulin Sales (Million US$), 2005 - 2009
Figure 4-2: Global - NovoRapid Insulin Sales (Million US$), 2005 - 2009
Figure 4-3: Global - Levemir Insulin Sales (Million US$), 2005 - 2009
Figure 4-4: Global - Humalog Insulin Sales (Million US$), 2006 - 2009
Figure 4-5: Global - Humulin Insulin Brand Sales (Million US$), 2006 - 2009
Figure 4-6: Global - Apidra Insulin Sales (Million US$), 2005 - 2009, Q1 2010
Figure 4-7: Apidra - Forecast for Insulin Sales (Million US$), 2009 - 2013
Figure 4-8: Global - Lantus Insulin Sales (Million US$), 2006 - 2009, Q1 2010
Figure 4-9: Global - Forecast for Lantus Insulin Sales (Million US$), 2010 - 2015
Figure 5-1: Global - Januvia DPP-IV Inhibitors Sales (Million US$), 2007 - 2009
Figure 5-2: Global - Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 - 2017
(c) Renub Research Page 9 of 18

---

Figure 5-3: Global - Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 - 2017
Figure 5-4: Global - Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 - 2017
Figure 5-5: Global - Galvus DPP-IV Inhibitors Sale (Million US$), 2007 - 2009
Figure 5-6: Global - Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 - 2012
Figure 6-1: Global - Byetta GLP-1 Sales (Million US$), 2006 - 2009
Figure 6-2: Global - Forecast for Byetta GLP-1 Sales (Million US$), 2010 - 2017
Figure 6-3: Global - Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 - 2017
Figure 6-4: Global - Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 - 2017
Figure 6-5: Global - Forecast for Syncria GLP-1 Sales (Million US$), 2013 - 2017
Figure 6-6: Global - Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 - 2017
Figure 8-1: India - Number of People with Diabetes (Million), 2003, 2007, 2010
Figure 8-2: India - Diabetes Drug Market (Billion INR), 2006 - 2009
Figure 8-3: India - Forecast for Diabetes Drug Market (Billion INR), 2010 - 2014
Figure 8-4: India - Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in
Percent), 2003 & 2007
Figure 8-5: India - Insulin Market (Million INR), 2006 - 2009
Figure 8-6: India - Forecast for Insulin Market (Million INR), 2010 - 2014
Figure 8-7: China - Number of Diabetes Patients (Million), 2003, 2007 & 2010
Figure 8-8: China - Diabetes Drug Market (Billion Yuan), 2006 - 2009E
Figure 8-9: China - Forecast for Diabetes Drug Market (Billion Yuan) 2010 - 2014
Figure 8-10: China - Insulin Market (Million Yuan), 2007 - 2009
Figure 8-11: China - Forecast for Insulin Market (Million Yuan), 2010 - 2014
Figure 8-12: USA - Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010
Figure 8-13: USA - Diabetes Drug Market (Million US$), 2002 - 2009
Figure 8-14: USA - Forecast for Diabetes Drug Market (Million US$), 2010 - 2014
Figure 8-15: USA - Insulin Market (Billion US$), 2003 - 2009
Figure 8-16: USA - Forecast for Insulin Market (Billion US$), 2010 - 2014
Figure 8-17: Brazil - Diabetes Population (Million), 2003, 2007 & 2010
Figure 8-18: Brazil - Diabetes Drug Market (Million US$), 2008 - 2013
Figure 8-19: Russia - Number of Diabetes Population (Million), 2005 & 2010
Figure 8-20: Russia - Insulin Market (Million US$), 2002, 2005 - 2009
Figure 8-21: Russia - Forecast for Insulin Market (Million US$), 2010 - 2014
Figure 8-22: Japan - Number of Diabetes Population (Million), 2003 - 2010
Figure 8-23: Japan - Diabetes Drug Market (Million US$), 2002 - 2009
Figure 8-24: Japan - Forecast for Diabetes Market (Million US$), 2010 - 2014
Figure 8-25: Japan - Insulin Market (Million US$), 1998 - 2009
Figure 8-26: Japan - Forecast for Insulin Market (Million US$), 2010 - 2014
(c) Renub Research Page 10 of 18

---